Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic

Published:2020-06-04 Issue:7 Volume:34 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Kasperkiewicz M.¹^ORCID,Schmidt E.²³,Fairley J.A.⁴,Joly P.⁵^ORCID,Payne A.S.⁶,Yale M.L.⁷,Zillikens D.²,Woodley D.T.¹

Affiliation:

1. Department of Dermatology Keck School of Medicine University of Southern California Los Angeles CA USA

2. Department of Dermatology University of Lübeck Lübeck Germany

3. Lübeck Institute of Experimental Dermatology (LIED) University of Lübeck Lübeck Germany

4. Department of Dermatology University of Iowa Iowa City IA USA

5. Department of Dermatology Rouen University Hospital Rouen France

6. Department of Dermatology University of Pennsylvania Philadelphia PA USA

7. International Pemphigus and Pemphigoid Foundation Sacramento CA USA

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16525

Reference5 articles.

2. Pemphigoid diseases

3. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

4. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

5. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study;Dermatologica Sinica;2024-01

2. The Impact of the Initial Phase of the COVID-19 Pandemic on Patients With Autoimmune Bullous Diseases;Cureus;2023-09-19

3. The Management of Autoimmune Bullous Skin Disorders in the Era of COVID-19 Pandemic: A Single Center, Retrospective, Cross-sectional Study;Journal of the Turkish Academy of Dermatology;2023-06-21

4. Case report: A case of epidermolysis bullosa acquisita with IgG and IgM anti-basement membrane zone antibodies relapsed after COVID-19 mRNA vaccination;Frontiers in Medicine;2023-05-30

5. COVID-19 and autoimmune bullous diseases: Lessons learned;Autoimmunity Reviews;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3